title: Reply to A. Ota et al, Y.H. Kim, and N. Van Der Steen et al.
authors.affiliation: James Chih-Hsin Yang, National Taiwan University Hospital, Taipei, Taiwan; Tarun Puri, Eli Lilly, Gurgaon, Haryana, India; Mauro Orlando, Eli Lilly Interamérica, Buenos Aires, Argentina; and Ying Cheng, Jilin Provincial Cancer Hospital, Changchun, China.
authors.forename: James Chih-Hsin
authors.initials: JC
authors.lastname: Yang
authors.affiliation: James Chih-Hsin Yang, National Taiwan University Hospital, Taipei, Taiwan; Tarun Puri, Eli Lilly, Gurgaon, Haryana, India; Mauro Orlando, Eli Lilly Interamérica, Buenos Aires, Argentina; and Ying Cheng, Jilin Provincial Cancer Hospital, Changchun, China.
authors.forename: Tarun
authors.initials: T
authors.lastname: Puri
authors.affiliation: James Chih-Hsin Yang, National Taiwan University Hospital, Taipei, Taiwan; Tarun Puri, Eli Lilly, Gurgaon, Haryana, India; Mauro Orlando, Eli Lilly Interamérica, Buenos Aires, Argentina; and Ying Cheng, Jilin Provincial Cancer Hospital, Changchun, China.
authors.forename: Mauro
authors.initials: M
authors.lastname: Orlando
authors.affiliation: James Chih-Hsin Yang, National Taiwan University Hospital, Taipei, Taiwan; Tarun Puri, Eli Lilly, Gurgaon, Haryana, India; Mauro Orlando, Eli Lilly Interamérica, Buenos Aires, Argentina; and Ying Cheng, Jilin Provincial Cancer Hospital, Changchun, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Cheng
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung; D003131:Combined Modality Therapy; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms; D000068437:Pemetrexed
chemical_list: D000068437:Pemetrexed; D000077156:Gefitinib